1
|
Popov SV, Maslov LN, Mukhomedzyanov AV, Kurbatov BK, Gorbunov AS, Kilin M, Azev VN, Khlestkina MS, Sufianova GZ. Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling. Pharmaceutics 2023; 15:pharmaceutics15031029. [PMID: 36986889 PMCID: PMC10056827 DOI: 10.3390/pharmaceutics15031029] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 03/03/2023] [Accepted: 03/16/2023] [Indexed: 03/30/2023] Open
Abstract
In-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is 5-6%. Consequently, it is necessary to develop fundamentally novel drugs capable of reducing mortality in patients with acute myocardial infarction. Apelins could be the prototype for such drugs. Chronic administration of apelins mitigates adverse myocardial remodeling in animals with myocardial infarction or pressure overload. The cardioprotective effect of apelins is accompanied by blockage of the MPT pore, GSK-3β, and the activation of PI3-kinase, Akt, ERK1/2, NO-synthase, superoxide dismutase, glutathione peroxidase, matrix metalloproteinase, the epidermal growth factor receptor, Src kinase, the mitoKATP channel, guanylyl cyclase, phospholipase C, protein kinase C, the Na+/H+ exchanger, and the Na+/Ca2+ exchanger. The cardioprotective effect of apelins is associated with the inhibition of apoptosis and ferroptosis. Apelins stimulate the autophagy of cardiomyocytes. Synthetic apelin analogues are prospective compounds for the development of novel cardioprotective drugs.
Collapse
Affiliation(s)
- Sergey V Popov
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Leonid N Maslov
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Alexandr V Mukhomedzyanov
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Boris K Kurbatov
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Alexandr S Gorbunov
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Michail Kilin
- Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia
| | - Viacheslav N Azev
- Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, The Russian Academy of Sciences, Pushchino 142290, Russia
| | - Maria S Khlestkina
- Department of Pharmacology, Tyumen State Medical University, Tyumen 625023, Russia
| | - Galina Z Sufianova
- Department of Pharmacology, Tyumen State Medical University, Tyumen 625023, Russia
| |
Collapse
|
2
|
Retraction: Apelin Receptor (APJ) Expression during Cardiopulmonary Bypass in Children Undergoing Surgical Repair. PLoS One 2018; 13:e0202136. [PMID: 30080885 PMCID: PMC6078176 DOI: 10.1371/journal.pone.0202136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
3
|
Peyronnet R, Bollensdorff C, Capel RA, Rog-Zielinska EA, Woods CE, Charo DN, Lookin O, Fajardo G, Ho M, Quertermous T, Ashley EA, Kohl P. Load-dependent effects of apelin on murine cardiomyocytes. PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY 2017; 130:333-343. [PMID: 28935153 PMCID: PMC5726609 DOI: 10.1016/j.pbiomolbio.2017.09.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2017] [Revised: 09/07/2017] [Accepted: 09/08/2017] [Indexed: 01/26/2023]
Abstract
The apelin peptide is described as one of the most potent inotropic agents, produced endogenously in a wide range of cells, including cardiomyocytes. Despite positive effects on cardiac contractility in multicellular preparations, as well as indications of cardio-protective actions in several diseases, its effects and mechanisms of action at the cellular level are incompletely understood. Here, we report apelin effects on dynamic mechanical characteristics of single ventricular cardiomyocytes, isolated from mouse models (control, apelin-deficient [Apelin-KO], apelin-receptor KO mouse [APJ-KO]), and rat. Dynamic changes in maximal velocity of cell shortening and relaxation were monitored. In addition, more traditional indicators of inotropic effects, such as maximum shortening (in mechanically unloaded cells) or peak force development (in auxotonic contracting cells, preloaded using the carbon fibre technique) were studied. The key finding is that, using Apelin-KO cardiomyocytes exposed to different preloads with the 2-carbon fibre technique, we observe a lowering of the slope of the end-diastolic stress-length relation in response to 10 nM apelin, an effect that is preload-dependent. This suggests a positive lusitropic effect of apelin, which could explain earlier counter-intuitive findings on an apelin-induced increase in contractility occurring without matching rise in oxygen consumption.
Collapse
Affiliation(s)
- Rémi Peyronnet
- Institute for Experimental Cardiovascular Medicine, University Heart Centre Freiburg · Bad Krozingen, Medical School of the University of Freiburg, Germany; Imperial College London, NHLI, Heart Science Centre, UK.
| | - Christian Bollensdorff
- Imperial College London, NHLI, Heart Science Centre, UK; Sidra Medical and Research Center, Qatar Foundation, Qatar
| | | | - Eva A Rog-Zielinska
- Institute for Experimental Cardiovascular Medicine, University Heart Centre Freiburg · Bad Krozingen, Medical School of the University of Freiburg, Germany; Imperial College London, NHLI, Heart Science Centre, UK
| | - Christopher E Woods
- Stanford University Division of Cardiovascular Medicine, Stanford, USA; Palo Alto Medical Foundation, Burlingame, CA, USA
| | - David N Charo
- Stanford University Division of Cardiovascular Medicine, Stanford, USA
| | - Oleg Lookin
- Ural Branch of the Russian Academy of Sciences, Ekaterinburg, Russian Federation
| | - Giovanni Fajardo
- Stanford University Division of Cardiovascular Medicine, Stanford, USA
| | - Michael Ho
- Stanford University Division of Cardiovascular Medicine, Stanford, USA
| | | | - Euan A Ashley
- Stanford University Division of Cardiovascular Medicine, Stanford, USA
| | - Peter Kohl
- Institute for Experimental Cardiovascular Medicine, University Heart Centre Freiburg · Bad Krozingen, Medical School of the University of Freiburg, Germany; Imperial College London, NHLI, Heart Science Centre, UK
| |
Collapse
|